Profile data is unavailable for this security.
About the company
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
- Revenue in USD (TTM)5.05m
- Net income in USD-46.90m
- Incorporated1989
- Employees60.00
- LocationArmata Pharmaceuticals Inc5005 Mcconnell AveLOS ANGELES 90066United StatesUSA
- Phone+1 (310) 665-2928
- Fax+1 (310) 665-2963
- Websitehttps://www.armatapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -56.17m | 264.00m | 17.00 | -- | 12.62 | -- | -- | -1.80 | -1.80 | 0.00 | 0.2852 | 0.00 | -- | -- | 0.00 | -159.13 | -77.37 | -195.99 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
| Rezolute Inc | 0.00 | -77.18m | 270.76m | 71.00 | -- | 1.81 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -54.73 | -47.11 | -58.50 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -22.76m | 290.41m | 38.00 | -- | 3.62 | -- | -- | -0.5591 | -0.5591 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -39.54 | -51.34 | -51.19 | -60.61 | -- | -- | -- | -44,190.40 | -- | -- | 0.0609 | -- | -- | -- | -45.44 | -- | -36.83 | -- |
| Immuneering Corp | 0.00 | -62.50m | 291.86m | 54.00 | -- | 1.26 | -- | -- | -1.78 | -1.78 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -40.37 | -46.52 | -42.64 | -49.48 | -- | -- | -- | -4,578.95 | -- | -- | 0.00 | -- | -- | -- | -14.15 | -- | 32.83 | -- |
| Amarin Corporation PLC | 226.73m | -86.19m | 292.97m | 275.00 | -- | 0.0319 | -- | 1.29 | -76.48 | -76.48 | 37.99 | 441.28 | 0.3215 | 0.4998 | 1.89 | 824,487.30 | -12.22 | -5.67 | -16.79 | -8.23 | 54.96 | 72.68 | -38.01 | -12.24 | 2.43 | -- | 0.00 | -- | -25.51 | -11.86 | -39.03 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 5.05m | -46.90m | 294.17m | 60.00 | -- | -- | -- | 58.20 | -1.30 | -1.30 | 0.1396 | -2.64 | 0.0538 | -- | 3.39 | 84,233.34 | -49.96 | -47.36 | -- | -60.79 | -- | -- | -928.00 | -829.99 | -- | -2.12 | 2.88 | -- | 14.24 | -- | 72.60 | -- | 53.02 | -- |
| PepGen Inc | 0.00 | -93.56m | 294.93m | 81.00 | -- | 1.81 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -43.19m | 306.23m | 9.00 | -- | 6.22 | -- | -- | -0.7217 | -0.7217 | 0.00 | 0.8185 | 0.00 | -- | -- | 0.00 | -44.27 | -34.06 | -57.79 | -38.07 | -- | -- | -- | -- | -- | -- | 0.2359 | -- | -- | -- | -48.77 | -- | -- | -- |
| Foghorn Therapeutics Inc | 24.52m | -72.12m | 306.34m | 112.00 | -- | -- | -- | 12.49 | -1.15 | -1.15 | 0.3896 | -1.59 | 0.0955 | -- | -- | 218,910.70 | -28.10 | -28.66 | -38.84 | -33.19 | -- | -- | -294.16 | -596.97 | -- | -- | -- | -- | -33.83 | -- | 11.99 | -- | -1.32 | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 310.31m | 18.00 | -- | 23.78 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| CytoDyn Inc | 0.00 | -40.35m | 312.52m | 13.00 | -- | -- | -- | -- | -0.0322 | -0.0322 | 0.00 | -0.0946 | 0.00 | -- | -- | 0.00 | -229.87 | -225.45 | -- | -- | -- | -- | -- | -184,742.10 | -- | -6.09 | -- | -- | -- | -- | 104.41 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 314.07m | 56.00 | -- | 0.9946 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 317.06m | 17.00 | -- | 1.79 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 323.00m | 95.00 | -- | 2.40 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Armata Pharmaceuticals Inc's reporting currency: US Dollar USD
2.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 305.62k | 0.84% |
| Geode Capital Management LLCas of 30 Sep 2025 | 104.55k | 0.29% |
| Edgewood Management LLCas of 30 Sep 2025 | 100.00k | 0.28% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 48.07k | 0.13% |
| Bridgeway Capital Management LLCas of 30 Sep 2025 | 44.68k | 0.12% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 41.30k | 0.11% |
| SeaCrest Wealth Management LLCas of 31 Dec 2025 | 40.99k | 0.11% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 40.30k | 0.11% |
| Grey Ledge Advisors LLCas of 30 Sep 2025 | 30.00k | 0.08% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 24.69k | 0.07% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
